"Making specialty medicines accessible to all"
We manufacture and market affordable medicines that comply with global standards and strive to achieve market leadership in domestic and international markets
The launch of a generic version of long-awaited complex blockbuster drug, Glatiramer Acetate in the USA market has catapulted the company to the next orbit in terms of its capability and credibility as a niche player in pharmaceutical sector.
Our products cover three main markets; international formulations, domestic formulations and APIs. Within these areas we are leaders in generic oncology and are taking steps to expand therapeutic segments with a continued focus on niche products.
Natco Trust was founded in 1995 with the desire to serve under-privileged children and poor people in society. As National Award winners For Excellence in CSR & Sustainability, we strongly believe in giving back to the communities in which we function.
In FY 2018-19, NATCO recorded consolidated total revenue of INR 22,247 million as against INR 22,424 million for the last year. The net profit for the period, on a consolidated basis, was INR 6,444 million, as against INR 6,962 million last year.
Share price at
Share price at class="XLloXe AP7Wnd">Natco Pharma
We provide a stimulating and challenging work environment for our employees, who get the opportunity to work with state-of-the-art technologies and deliver affordable and life saving drugs globally.
Whether you're a customer, job seeker, health professional or an investor, you can find the best way to contact us.